Business Context and Reporting Period
This Form 8-K was filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on February 5, 2021. The filing reports the entry into a material definitive agreement to establish an "At the Market" (ATM) equity offering program.
Key Financial Metrics and Transaction Details
- Offering Size: Up to $6,306,000 in aggregate offering price of common stock.
- Sales Agent: Ladenburg Thalmann & Co. Inc.
- Commission: Up to 3.0% of gross proceeds.
- Legal Fees: Reimbursement to the Agent for counsel fees up to $50,000 upon execution, plus up to $2,500 per calendar quarter for ongoing disbursements.
- Use of Proceeds: General corporate purposes and working capital.
- Trading Venue: NASDAQ Capital Market (Symbol: SLRX).
Material Changes
The filing does not report changes to historical financial performance (revenue, profit, or cash flow) as it is a current report regarding a new financing facility. The material change is the authorization of a new mechanism to raise capital through the sale of shares at prevailing market prices, subject to market demand and company discretion.
Guidance, Outlook, and Risks
- Management Discretion: The Company has no obligation to sell any shares and may suspend sales if they cannot be effected at or above a designated price.
- Termination: The offering terminates upon the sale of all eligible shares or earlier termination of the Sales Agreement.
- Regulatory Limits: Sales are subject to limitations under General Instruction I.B.6 of Form S-3. A new prospectus supplement is required if the Company seeks to offer more than $6,306,000.
- Outlook: Proceeds are intended to support working capital needs, indicating a focus on liquidity management.
Investor Verification Checklist
- Verify the current share price and volume on the NASDAQ Capital Market to assess potential dilution impact.
- Review the Company's most recent 10-K or 10-Q to understand current cash runway and working capital requirements.
- Check for any subsequent filings indicating the actual volume of shares sold under this ATM agreement.
- Confirm the total number of shares outstanding to calculate the percentage dilution if the full $6,306,000 is raised.